Blurbs

SVB Securities Sticks to Their Sell Rating for AbbVie (ABBV)

SVB Securities analyst David Risinger maintained a Sell rating on AbbVie (ABBVResearch Report) on August 1 and set a price target of $140.00. The company’s shares closed last Tuesday at $140.39.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of 0.3% and a 42.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $158.71.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $175.91 and a one-year low of $105.56. Currently, AbbVie has an average volume of 6.08M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Read More on ABBV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos